Fulcrum therapeutics announces recent business highlights and third quarter 2022 financial results

― selected 12mg as the dose for next cohort in the phase 1b trial of ftx-6058 in sickle cell disease (scd) ―

FULC Ratings Summary

FULC Quant Ranking